Researchers have discovered how to diagnose Alzheimer’s disease with more than 82 per cent accuracy by evaluating the interplay between four linguistic factors; and developing automated technology to detect these impairments.
UAB researchers have found that, contrary to current thinking, astrocytes are repelled by the amyloid plaques that are linked to the disease. pplying mathematical models used for studying the galaxies or interactions between elementary particles, researchers at the Institute of Neuroscience of the Universitat Autònoma de Barcelona, in collaboration with Massachusetts General Hospital, Boston, have analysed the spatial distribution of astrocytes: brain cells that are essential for the correct functioning of neurons.
In a quest to stay healthy, many people are seeking natural ways to prevent neurodegenerative diseases. Recent studies show that pomegranate extract, which is a rich source of disease-fighting polyphenols, can help protect against the development of Alzheimer's disease. But researchers weren't sure which molecules to thank. A team reports in ACS Chemical Neuroscience that the responsible compounds may be urolithins, which are made when gut bacteria break down the polyphenols in the extract.
Scientists have made several kinds of mice in the hope of mimicking ALS and frontotemporal dementia, diseases caused by mutations in the C9ORF72 gene. Early results indicate that the mutated genes generate unusual RNAs and proteins, but that losing the normal C9ORF72 gene does not kill neurons.
How fast elderly people walk may be related to the amount of amyloid they have built up in their brains, even if they don’t yet have symptoms of Alzheimer’s disease, according to a study published in the December 2, 2015, online issue of Neurology®, the medical journal of the American Academy of Neurology.
NYU Langone Medical Center has been awarded a five-year $7.5 million grant to provide caregivers for individuals with Alzheimer’s disease and other dementias with access to state-of-the-art support programs and services designed to improve quality of life. New York State Governor Andrew M. Cuomo announced in November that $67.6 million has been awarded to nine organizations across the state as part of his Alzheimer's Caregiver Support Initiative to develop programs that support family members and caregivers for New Yorkers living with Alzheimer’s and dementia.
In addition to treating depression, a commonly used antidepressant medication also protects against compounds that can cause memory loss and dementia, a Loyola University Medical Center study has found.
A University of California, Irvine research team is part of a $37 million national effort to identify biomarkers that will predict the onset of Alzheimer’s disease in people with Down syndrome. UCI pediatric neurologist Dr. Ira Lott and colleagues will receive $4.7 million of that funding from the National Institute on Aging to support his continuing work to uncover the mystery of progressive cognitive impairment seen in some people over 40 with Down syndrome.
Lewy body dementia is the second most common type of dementia after Alzheimer’s disease. But if you’re not familiar with it, you’re not alone. “Lewy body dementia is the most common disorder you’ve never heard of,” says Bradley Boeve, M.D., a Mayo Clinic neurologist who will speak at the International Dementia with Lewy Bodies Conference Dec. 1-4 in Fort Lauderdale, Florida.
Amyloid beta, the plaque that accumulates in the brains of people with Alzheimer’s disease, may also contribute to Alzheimer’s by interfering with normal blood flow in the brain, according to investigators UAB. In findings published Nov. 23 in the journal Brain, the team shows that when amyloid beta accumulates around blood vessels — where it is known as vascular amyloid — it appears to prevent the brain from properly regulating blood flow, which is essential to normal brain function.
Virginia Tech Carilion Research Institute scientists have uncovered a mechanism in the brain that could account for some of the neural degeneration and memory loss in people with Alzheimer’s disease. The researchers, together with scientists at the University of Alabama at Birmingham School of Medicine, discovered that a common symptom of Alzheimer’s disease – the accumulation of amyloid plaques along blood vessels – could be disrupting blood flow in the brain.
Older adults who take college courses may increase their cognitive capacity and possibly reduce their risk for developing Alzheimer’s disease or other forms of dementia, according to new research published by the American Psychological Association.
In a novel animal study design that mimicked human clinical trials, researchers at University of California, San Diego School of Medicine report that long-term treatment using a small molecule drug that reduces activity of the brain’s stress circuitry significantly reduces Alzheimer’s disease (AD) neuropathology and prevents onset of cognitive impairment in a mouse model of the neurodegenerative condition. The findings are described in the current online issue of the journal Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.
Changes in routine, including elaborate plans or scheduling special events, can have an adverse effect on someone suffering from any form of dementia.
Mayo Clinic’s Florida campus was awarded a $5.3 million grant from the National Institutes of Health (NIH) to identify vascular risk factors in aging and dementia, and translate that knowledge into studying potential targets for treatment.
A special orchestra for people with dementia has helped boost their confidence and mood, according to a new research project.
More than five million Americans and 15 million caregivers are impacted by Alzheimer's disease. A leading neuroscientist at Florida Atlantic University has developed eight myths and truths about this prevalent form of dementia.
Principal Investigator Takes Questions and Demonstrates Procedure with Video and Animation via Virtual Press Conference Tuesday, November 10th at 1:00 p.m. ET
Researchers from the University of Southampton have discovered a possible solution for side effects seen in immunotherapy treatment for Alzheimer’s disease.
The late Robin Williams had this form of dementia, which also can cause visual hallucinations and make depression worse. Until now, there has been no way to assess or operationalize many of the cognitive and behavioral symptoms of Lewy Body dementia in clinical practice.
An estrogen-like drug, raloxifene, has no demonstrated benefit on memory and thinking skills for women with dementia due to Alzheimer’s disease, according to a study published in the November 4, 2015, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Yesterday, Susan Williams, Robin Williams’ widow, spoke on Good Morning America (GMA) and in other media, about it taking the past year for her to learn that Robin was suffering from Lewy body dementia (LBD), which she believes led him to take his own life. Susan Williams explained that the original Parkinson’s diagnosis did not cover all of his symptoms, and he was unaware of the LBD diagnosis when he died.
Driving simulation and real-world data recording systems will shed light on brain health, functional abilities of people with neurological problems neurological disorders
New research suggests that older women who complain of memory problems may be at higher risk for experiencing diagnosed memory and thinking impairment decades later. The study is published in the October 28, 2015, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Chemical changes in brain cells caused by disturbances in the body’s day-night cycle may be a key underlying cause of the learning and memory loss associated with Alzheimer’s disease, according to a University of California, Irvine study.
The cost of care over the last five years of life for patients with dementia is significantly higher than for patients who die from heart disease, cancer, or other causes, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai, Dartmouth College and University of California, Los Angeles, and published online today in the journal Annals of Internal Medicine.
Although Lewy Body disease (LBD) is the second-most-common degenerative disease after Alzheimer’s disease (AD), it’s not exactly a household name. A fast, new test can assess clinical signs and symptoms of this disease, and discriminate between AD and LBD with 96
Using 10-year-old archival brain tissue from patients with Alzheimer’s disease, a research team from NYU Langone Medical Center has developed a novel method to examine the structure and function of proteins at the cell level -- providing greater means to study protein changes found in Alzheimer’s disease.
Evidence is mounting that drugs used to treat depression and Alzheimer’s disease also can help patients recover from strokes.
A new study, led by scientists at The Scripps Research Institute, the Veterans Affairs San Diego Healthcare System and University of California San Diego School of Medicine shows that increasing a crucial membrane protein in nerve cells within the brain can improve learning and memory in aged mice.
Researchers find a protein that's involved in helping control the architecture of connections between neurons – a basic process involved in both healthy and diseased brains.
A new and comprehensive study has found that celiac patients are at no increased risk for dementia before or after their diagnosis of celiac disease.
Neural stem cells transplanted into damaged brain sites in mice dramatically improved both motor and cognitive impairments associated with dementia with Lewy bodies, according to University of California, Irvine neurobiologists with the Sue & Bill Gross Stem Cell Research Center and the Institute for Memory Impairments and Neurological Disorders.
The new technique allows scientists to study diseases like Alzheimer’s and Parkinson’s using cells from human patients
The Nantz National Alzheimer Center at Houston Methodist Hospital is part of a landmark clinical trial that looks at removing a key protein from the brain to prevent memory loss at least a decade before symptoms are noticed in healthy older adults.
A multi-institutional team led by scientists at the Indiana University School of Medicine have discovered an immune system gene associated with higher rates of amyloid plaque buildup in the brains of Alzheimer’s patients and older adults at risk for the disease.
Women with a gene variant (APOEe4 allele) associated with Alzheimer’s disease experience a steeper decline in body mass index (BMI) after age 70 than those women without the version of the gene, whether they go on to develop dementia or not.
More than 100 of the world’s leading Alzheimer’s drug researchers will gather today and tomorrow at the Hyatt Regency Jersey City to hear the latest developments in the discovery and testing of promising drugs, detection technologies, biomarkers and newly discovered therapeutic targets for preventing, treating and curing Alzheimer’s disease and related dementias. Organized and hosted by the Alzheimer’s Drug Discovery Foundation, the conference is the only scientific meeting dedicated solely to bringing leading academic and industry scientists together to present new research on Alzheimer’s drug discovery and establish partnerships to further their studies.
Latest Research Highlights from ACSM— September 2015
Clumps of misfolded proteins are responsible for diseases ranging from Huntington’s, to diabetes and Alzheimer’s. McGill researchers hope to incrementally speed up the process of drug discovery for diseases such as these thanks to a new suite of computer tools they have developed.
A new science called Neurogastronomy brings chefs and neuroscientists together to improve quality of life for patients with taste & smell deficits. The inaugural International Society of Neurogastronomy symposium is November 7, 2015, featuring internationally-renowned chefs, scientists, and food technologists.
"This study has let us characterize the parameters of decline in people who will eventually develop Alzheimer's, which means we can better identify both benign symptoms and those that warrant particular attention." - Sylvie Belleville
Alzheimer’s disease, long thought to be a single disease, really consists of three distinct subtypes, according to a UCLA study.
The largest nationwide clinical trial to study high-dose resveratrol long-term in people with mild to moderate Alzheimer’s disease found that a biomarker that declines when the disease progresses was stabilized in people who took the purified form of resveratrol.
Researchers conducting clinical trials of drugs that might prevent AD are exploring how best to inform participants of their increased risk for the disease, and studying how they cope with this information. Alzforum reports in a two-part series.
In a consensus paper, a global panel of leading aging experts suggests physicians routinely screen everyone older than 70 annually for cognitive problems.
The aging of the population, shifting diagnostic criteria, and new health care policy initiatives are some of the factors driving changes in mental health treatment for older Americans, according to the September special issue of the Harvard Review of Psychiatry. The journal is published by Wolters Kluwer.
An estimated 5.3 million people in the U.S. suffer from Alzheimer’s disease (AD). The five current FDA-approved AD medications only help mask the disease symptoms instead of treating the underlying disease. In a new study, researchers used IRL-1620, a chemical that binds to endothelin B receptors, to treat AD in rats.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right